手术所致子宫内膜创伤相关宫腔粘连的流行病学、临床负担与预防:系统文献综述与选择性荟萃分析
该系统性文献综述与选择性荟萃分析纳入249篇文献,评估了早期妊娠丢失清宫术后、宫腔镜子宫肌瘤剔除术后及宫腔镜子宫纵隔矫形术后新发宫腔粘连(IUA)的风险分别为17%、16%和28%。宫腔内凝胶屏障辅助预防可降低上述术后IUA风险(相对风险0.45、0.38、0.29)。宫腔粘连分离术后未用辅助剂者IUA复发率为35%,使用宫内球囊或宫内节育器者复发率分别为43%和未报告具体值。
要点
- 早期妊娠丢失清宫术后、宫腔镜子宫肌瘤剔除术后及宫腔镜子宫纵隔矫形术后新发IUA风险分别为17%、16%、28%。
- 宫腔内凝胶屏障辅助预防可降低上述三种术后IUA风险,相对风险分别为0.45、0.38、0.29。
- 宫腔粘连分离术后未用辅助剂者IUA复发率为35%,使用宫内球囊者为43%,使用宫内节育器者复发率原文报告为27-59%。
核心结论
- 即使行宫腔粘连分离术,被认为促进IUA形成的基底层子宫内膜创伤可能持续存在并导致不良生殖结局。
- 关于子宫内膜创伤和IUA的发病机制、预防和管理仍存在许多关键知识空白。
研究设计与样本
- 系统文献综述与选择性荟萃分析,检索PubMed、Embase和Cochrane数据库,遵循PRISMA指南,纳入英文文献至2024年11月8日。
- 共纳入249篇合适文献,仅对数据充分的结果进行荟萃分析,报告比例(95%CI)、异质性(I2)及每项纳入研究的偏倚风险。
- 使用美国NIH干预性和观察性研究工具进行偏倚风险评估。
- PROSPERO注册号:CRD42023366218。
主要发现
- 早期妊娠丢失清宫术后新发IUA风险为17%(95%CI:11-25%;13项研究,I2=87%,证据质量差至好)。
- 宫腔镜子宫肌瘤剔除术后新发IUA风险为16%(95%CI:6-28%;8项研究,I2=93%,证据质量一般至好)。
- 宫腔镜子宫纵隔矫形术后新发IUA风险为28%(95%CI:13-46%;8项研究,I2=91%,证据质量一般至好)。
- 宫腔粘连分离术后未用辅助剂者IUA复发率为35%(95%CI:24-46%;13项研究,I2=95%,证据质量差至好),使用宫内球囊者为43%(95%CI:35-51%;14项研究,I2=85%,证据质量差至好),使用宫内节育器者复发率为27-59%(95%CI:27-59%;4项研究,I2=85%,证据质量一般至好)。
- 凝胶屏障用于二级预防的复发率为28%(95%CI:4-62%;3项研究,I2=94%,证据质量好)。
关键数值与推荐
- 早期妊娠丢失清宫术后、宫腔镜子宫肌瘤剔除术后及宫腔镜子宫纵隔矫形术后使用宫腔内凝胶屏障辅助预防IUA的相对风险分别为0.45(95%CI:0.30-0.68;3项研究,I2=0%,证据质量差至好)、0.38(95%CI:0.20-0.73;3项研究,I2=0%,证据质量一般)和0.29(95%CI:0.12-0.69;3项研究,I2=0%,证据质量一般至好)。
- 早期妊娠丢失清宫术后新发IUA风险为17%(95%CI:11-25%;13项研究,I2=87%,证据质量差至好)。
- 宫腔镜子宫肌瘤剔除术后新发IUA风险为16%(95%CI:6-28%;8项研究,I2=93%,证据质量一般至好)。
- 宫腔镜子宫纵隔矫形术后新发IUA风险为28%(95%CI:13-46%;8项研究,I2=91%,证据质量一般至好)。
- 宫腔粘连分离术后未用辅助剂者IUA复发率为35%(95%CI:24-46%;13项研究,I2=95%,证据质量差至好),使用宫内球囊者为43%(95%CI:35-51%;14项研究,I2=85%,证据质量差至好),使用宫内节育器者复发率为27-59%(95%CI:27-59%;4项研究,I2=85%,证据质量一般至好),凝胶屏障用于二级预防的复发率为28%(95%CI:4-62%;3项研究,I2=94%,证据质量好)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 早期妊娠丢失清宫术后新发IUA风险的荟萃分析异质性I2=87%。
- 宫腔镜子宫肌瘤剔除术后新发IUA风险的荟萃分析异质性I2=93%。
- 宫腔镜子宫纵隔矫形术后新发IUA风险的荟萃分析异质性I2=91%。
- 宫腔粘连分离术后未用辅助剂者IUA复发率的荟萃分析异质性I2=95%。
- 使用宫内球囊者IUA复发率的荟萃分析异质性I2=85%,使用宫内节育器者异质性I2=85%,凝胶屏障用于二级预防的复发率异质性I2=94%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reproductive-age women with intrauterine adhesions (IUAs) following uterine surgery may be asymptomatic or may experience light or absent menstruation, infertility, preterm delivery, and/or peripartum hemorrhage. Understanding procedure- and technique-specific risks and the available evidence on the impact of surgical adjuvants is essential to the design of future research. OBJECTIVE AND RATIONALE: While many systematic reviews have been published, most deal with singular aspects of the problem. Consequently, a broadly scoped systematic review and selective meta-analyses identifying evidence strengths and gaps are necessary to inform future research and treatment strategies. SEARCH METHODS: A systematic literature review was performed seeking evidence on IUA incidence following selected uterine procedures and the effectiveness of hysteroscopic adhesiolysis on menstrual, endometrial, fertility, and pregnancy-related outcomes. An evaluation of the impact of surgical adjuvants designed to facilitate adhesion-free endometrial repair was included. Searches were conducted in the PubMed, Embase, and Cochrane databases following PRISMA guidelines and included English-language publications from inception to 8 November 2024. Inclusion criteria restricted articles to those reporting IUA epidemiology or related clinical outcomes. Risk of bias assessment used the US NIH tools for interventional and observational studies. Meta-analyses were conducted and reported only for outcomes where there were sufficient data. Per analysis, we report on proportions (with 95% CI), heterogeneity (I2), and the risk of bias for each study included. OUTCOMES: The review identified 249 appropriate publications. The risks of new-onset IUAs following the removal of products of conception after early pregnancy loss, hysteroscopic myomectomy, and hysteroscopic metroplasty for septum correction were 17% (95% CI: 11-25%; 13 studies, I2 = 87%, poor to good evidence quality), 16% (95% CI: 6-28%; 8 studies, I2 = 93%, fair to good evidence quality), and 28% (95% CI: 13-46%; 8 studies, I2 = 91%, fair to good evidence quality), respectively. For primary IUA prevention with adjuvant intrauterine gel barriers, the relative risks were 0.45 (95% CI: 0.30-0.68; three studies, I2 = 0%, poor to good evidence quality), 0.38 (95% CI: 0.20-0.73; three studies, I2 = 0%, fair evidence quality), and 0.29 (95% CI: 0.12-0.69; three studies, I2 = 0%, fair to good evidence quality), respectively, following the above potentially adhesiogenic procedures. Following adhesiolysis without adjuvants, the IUA recurrence rate was 35% (95% CI: 24-46%; 13 studies, I2 = 95%, poor to good evidence quality), similar to the rate of 43% for both those treated adjuvantly with an intrauterine balloon (95% CI: 35-51%; 14 studies, I2 = 85%, poor to good evidence quality), or an IUD (95% CI: 27-59%; four studies, I2 = 85%, fair to good evidence quality). The recurrence rate for secondary prevention with gel barriers was 28% (95% CI: 4-62%; three studies, I2 = 94%, good evidence quality). Notably, there was an excess rate of associated adverse obstetrical outcomes, including preterm delivery, placenta accreta spectrum, placenta previa, peripartum hemorrhage, and hysterectomy, with evidence demonstrating the beneficial impact of adjuvant therapies on these outcomes. WIDER IMPLICATIONS: This systematic review comprehensively analyzes IUA formation following uterine surgical procedures and adjuvant therapy effectiveness. Even following adhesiolysis, it is apparent that the basilar endometrial trauma thought to facilitate the formation of IUAs may persist and contribute to adverse reproductive outcomes. Many critical gaps remain in our knowledge of the pathogenesis, prevention, and management of endometrial trauma and IUAs. PREGISTRATION NUMBER: PROSPERO (ID: CRD42023366218).
引用
- Munro MG, Salazar CA, Bhagavath B, et al. The epidemiology, clinical burden, and prevention of intrauterine adhesions (IUAs) related to surgically induced endometrial trauma: a systematic literature review and selective meta-analyses. Hum Reprod Update. 2025. PMID: 40914965. doi:10.1093/humupd/dmaf019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。